

Branched Chain Amino Acid, Meat Intake and Risk of Type 2 Diabetes in the Women's Health Initiative

Masoud Isanejad ¹; Andrea LaCroix ²; Cynthia A. Thomson ³; Lesley Tinker ⁴; Joseph C Larson ⁴; Qibin Qi ⁵; Lihong Qi ⁶; Rhonda M Cooper-DeHoff ⁷; Lawrence S Phillips ⁸; Ross L Prentice ⁴; Jeannette M Beasley ⁹.

¹ Institute of Public Health and Clinical Nutrition, University of Eastern Finland.

² Division of Epidemiology, University of California San Diego School of Medicine, San Diego, CA.

³ College of Public Health, University of Arizona.

⁴ Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA.

⁵ Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY.

⁶ Division of Biostatistics, Department of Public Health Sciences, UC Davis, Davis, CA.

⁷ Pharmacotherapy and Translational Research, University of Florida, Gainesville, FL.

⁸ Atlanta VA Medical Center, Decatur, GA; Division of Endocrinology, Emory University School of Medicine, Atlanta, GA.

⁹ Division of General Internal Medicine and Clinical Innovation, NYU School of Medicine, New York, New York.

Corresponding Authors:

Jeannette M. Beasley, PhD, MPH, RD, Assistant Professor

Department of Medicine, NYU School of Medicine, 462 First Avenue, OBV-CD673, New York, NY 10016.

646-501-4681 (phone)

212-263-8788 (fax)

Masoud Isanejad

Institute of Public Health and Clinical Nutrition, University of Eastern Finland, P.O. Box 1627 Kuopio, Finland.

+358- 449753845 (phone)

masoud.isanejad@uef.fi (email)

Last names for PubMed indexing: Isanejad, LaCroix, Thomson, Tinker, Larson, Qi, Qi, Cooper-DeHoff, Phillips, Prentice, Beasley.

Shortened version of the title: Branch chained amino acids and type 2 diabetes.

List of abbreviations: BCAA (branch chain amino acid); BMI (body mass index); CT (clinical trial); DM (dietary modification); DM-C (dietary modification trial comparison); FFQ (food frequency questionnaire); NBS (Nutritional Biomarkers Study); OS (observational study); T2D (type 2 diabetes); WHI (Women's Health Initiative Study);

1 **Abstract**

2 Knowledge regarding association of dietary branched chain amino acid (BCAA) and type 2 diabetes
3 (T2D), and the contribution of BCAA from meat to the risk of T2D are scarce. We evaluated
4 associations between dietary BCAA intake, meat intake, interaction between BCAA and meat intake
5 and risk of T2D. Data analyses were performed for 74,155 participants aged 50–79 y at baseline from
6 the Women's Health Initiative for up to 15 years of follow-up. We excluded from analysis participants
7 with treated T2D, and factors potentially associated with T2D or missing covariate data. The BCAA
8 and total meat intake was estimated from food frequency questionnaire (FFQ). Using Cox proportional
9 hazards models assessed the relationship between BCAA intake, meat intake, and T2D, adjusting for
10 confounders. A 20% increment in total BCAA intake (g/day and %energy) was associated with a 7%
11 higher risk for T2D (HR: 1.07; 95% CI: 1.05-1.09). For total meat intake, a 20% increment was
12 associated with a 4% higher risk of T2D (HR: 1.04; 95% CI: 1.03-1.05). The associations between
13 BCAA intake and T2D were attenuated but remained significant after adjustment for total meat intake.
14 These relations did not materially differ with or without adjustment for BMI. Our results suggest that
15 dietary BCAAs and meat intake are positively associated with T2D among postmenopausal women.
16 The association of BCAA and diabetes risk was attenuated but remained positive after adjustment for
17 meat intake suggesting that BCAA intake in part but not in full is contributing to the association of
18 meat with T2D risk.

19 INTRODUCTION

20 Dietary protein, comprised of amino acids, is an important modulator of glucose metabolism,
21 insulin sensitivity, and, therefore, T2D ⁽¹⁾. Higher dietary protein intake has been associated with
22 reduction in total energy intake and as a result may play a role in therapeutic care for individuals with
23 obesity-related chronic disease, including T2D ⁽²⁾. Contrary to this evidence, emerging data from
24 epidemiological studies have suggested a positive association between higher protein and meat intake
25 and incident T2D ⁽²⁻⁷⁾, despite protein's role in enhancing satiety and diet-induced thermogenesis. The
26 association of protein intake and risk of T2D has been studied in two large populations that included
27 thousands of incident T2D cases over 8-12 years of follow-up ^(6, 8). In particular, in the Women's
28 Health Initiative (WHI) ⁽⁶⁾ study, a ~20% increase in protein intake (corresponding to ~12 g protein and
29 3.4% energy from protein) was associated with a 5% higher risk of T2D. In the MALMO study ⁽⁸⁾, **in**
30 **72,992 women from the Nurses' Health Study, 92,088 women from Nurses' Health Study II and 40,722**
31 **men from the Health Professionals Follow-up Study**; participants in the highest quintiles of percentage
32 of energy derived from total protein and animal protein (21.6 % of Energy) had 7% higher risks of T2D
33 compared with those in the lowest quintiles (14.8 % of Energy).

34 Of note, a pooled analysis encompassing over four million person-years of follow-up and
35 15,580 cases of T2D suggested animal protein was associated with higher, whereas vegetable protein
36 was associated with lower, risk of T2D ⁽⁸⁾. These results suggest that protein source, in addition to
37 quantity, may be related to the development of T2D. In fact, higher consumption of meat, particularly
38 red meat, has been associated with a higher risk of T2D ⁽⁹⁾. Overall, it is unclear whether it is the
39 protein or other characteristics (i.e. nutrients, cooking methods) of protein-rich foods which explain the
40 association with T2D.

41 One postulated explanation for the differential results is that higher animal protein intake may
42 result in higher intake of branched chain amino acids (BCAA). BCAAs are essential amino acids that
43 need to be obtained from diet, which can be found mostly in meat, chicken, fish, dairy products and
44 eggs ⁽¹⁰⁾. BCAAs (leucine, isoleucine and valine) have a critical role in promoting skeletal muscle mass
45 as well as glucose uptake within the muscle ^(2, 11). Circulating BCAAs are positively associated with
46 insulin resistance, as measured by HOMA and Hemoglobin A1c (HbA1C) ⁽¹²⁻¹⁴⁾. Recent data from the
47 Nurses' Health Studies (I and II) and the Health Professionals Follow-up Study suggest total and
48 animal protein are associated with higher risk of T2D ⁽⁸⁾. What is less clear is whether BCAA may be

49 systemically elevated in response to an unfavorable and accelerated degradation to these important
50 diet-derived compounds during a metabolically perturbed state rather than causal in insulin resistance
51 development. The purpose of this analysis is to expand upon earlier findings in WHI relating protein
52 intake to T2D risk by evaluating the associations of BCAA and meat intake and risk of T2D within the
53 WHI, a large cohort of racially and ethnically diverse postmenopausal women, and the impact of
54 jointly adjusting for BCAA and meat intake on the risk of T2D.

55 **SUBJECTS AND METHODS**

56 *The WHI*

57 The design and baseline descriptions of the WHI studies have been published⁽¹⁵⁻¹⁷⁾. Data for the
58 present study were selected from the WHI clinical trials (CT) (Dietary Modification, Control Arm
59 (DM-C), Hormone Therapy, and Calcium/Vitamin D), and WHI observational study (OS). Briefly,
60 68,132 and 93,676 generally healthy postmenopausal women aged 50–79 y were enrolled in the CT or
61 the OS at 40 clinical centers across the United States between 1993 and 1998.

62 Incident T2D during follow-up was documented by self-report at each semiannual contact when
63 participants were asked by self-administered medical history update questionnaire, “Since the date
64 given on the front of this form, has a doctor prescribed any of the following pills or treatments?”
65 Choices included “pills for diabetes” and “insulin shots for diabetes.” Data from a WHI T2D
66 confirmation study showed that prevalent and incident T2D were consistent (self-reported treated
67 diabetes was concordant with the medication inventory in 79% of CT, and 77% in the OS participants)
68 with medication inventories of oral agents or insulin. Demographic and risk exposure data, as well as
69 data regarding family and medical history, were obtained by self-report using standardized
70 questionnaires. WHI-certified staff took physical measurements using standardized equipment,
71 including blood pressure, height and weight, and blood samples at the clinic visit⁽¹⁵⁾.

72 *Assessment of dietary intake*

73 Dietary intake was estimated using the food frequency questionnaire (FFQ) designed for the
74 WHI that was administered to all participants at baseline⁽¹⁸⁾. For participants in the dietary
75 modification trial the baseline FFQ was used for screening eligibility in relation to fat intake and the
76 intervention arm received support to change diet in a way that would alter meat and BCAA intake. As

77 such, in DM women only the control arm year 1 FFQ was used in this analysis of nutrient intake.
78 Nutrient intake including BCAA content was derived from the USDA nutrient database ⁽¹⁹⁾. To
79 determine total BCAA intake we calculated the sum of isoleucine, leucine and valine consumption
80 from the usual dietary intake.

81 *Calibration of Dietary Protein Intake*

82 As previously described ⁽⁶⁾, the WHI-Nutritional Biomarkers Study (WHI-NBS) sub-study
83 developed biomarker-based calibration equations to reduce measurement error in self-reported intake
84 of energy and protein by using linear regression models that predicted true intakes of energy and
85 protein given the self-reported intake and data on study subject characteristics ⁽⁶⁾.

86 Baseline (as described above) FFQ energy, BCAAs, and BCAA density served as the
87 uncalibrated baseline nutrient consumption estimates. For the calibrated energy and protein, logs of
88 nutrient consumption were obtained directly from the biomarker measurements for the 276 DM-C
89 women included in the WHI-NBS. For women not in the WHI-NBS, the WHI-NBS calibration
90 equations were applied ⁽⁶⁾. To estimate grams of calibrated BCAA, we multiplied the proportion of
91 BCAA: total uncalibrated protein in grams by calibrated protein.

92 *Analytic data set*

93 We excluded from analysis participants with treated T2D, i.e., those who reported T2D at enrollment
94 (n=6447) or during the first year of follow-up for the DM-C (n = 217) to correspond with the FFQ
95 analysis time points. To align the participant characteristics of the DM-C and other participants for
96 these analyses, we then applied the following DM trial exclusionary criteria to all participants in the
97 analysis sample: breast or colorectal cancer ever (n=5,566), other cancer (except non-melanoma skin
98 cancer) within 10 y preceding enrollment (n = 2,667), stroke or acute myocardial infarction 6 months
99 before enrollment (n = 115), BMI <18 (n =774), hypertension (>200/>105 mm Hg) (n = 224), FFQ
100 reported daily energy intake of <600 kcal or >5000 kcal) (n =4,706), ≥10 meals prepared away from
101 home per week (n =4,749), special low-fiber diet (n = 568), special diet due to malabsorption (n = 510),
102 and unintentional weight loss of >15 lb (6.8 kg) in the 6 months preceding baseline (n = 486)
103 (**Supplemental figure 1**). Finally, 17,518 participants were excluded with missing model covariate
104 data. After the above exclusion criteria were applied and the participants with complete data were
105 selected, the analytic data set included 32,024 CT and 62,241 OS participants. The WHI and NBS

106 protocol and consent forms were approved by the Institutional Review Board for each participating
107 institution and the Clinical Coordinating Center (Fred Hutchinson Cancer Research Center, Seattle,
108 WA).

109 *Statistical Analysis*

110 We performed a secondary analysis using subsample of WHI CT and OS data. Demographic
111 and health characteristics are reported by quintile of baseline total BCAA intake (sum of valine,
112 leucine, and isoleucine), as estimated from the FFQ. Accompanying p-values for trend derived from
113 either linear (continuous, ordinal demographics) or logistic (dichotomous) regression models with the
114 demographic of interest as a function of linear trend over quintiles (quintile 1 = 1, quintile 2 = 2, etc.).
115 Follow-up times started with the dietary modification comparison at year 1 or the OS at year 3 and
116 continued to the earliest of treated diabetes, death, or loss to follow-up ⁽⁶⁾.

117 For analysis, BCAA intake was characterized as absolute (g/day), relative to energy intake (%
118 energy/day), and relative to protein intake (% protein/day). Using Cox proportional hazards models, the
119 relationship between BCAA intake (modelled continuously for a 20 percent increase and categorically
120 by quintiles) and T2D is reported by hazard ratio (HR) and the corresponding 95% confidence intervals
121 (CI). To be comparable with our prior analysis ⁽⁶⁾, the final model was adjusted for age, race/
122 ethnicity, BMI, education, income, history of CHD, current smoking, current alcohol use, physical
123 activity, hypertension, family history of T2D, hormone use, glycemic load, glycemic index, and total
124 energy intake. **Models were additionally stratified within the model by the hormone therapy arms and
125 5-year age groups.** Trend p-values across quintiles are computed from separate proportional hazards
126 models with the outcome of interest as a function of linear trend over quintiles. Similarly, we assessed
127 associations between meat intake and T2D, as categorized by My Pyramid Equivalents Database
128 (MPED) categories. **In sensitivity analyses, we further adjusted BCAA intake for total meat intake and
129 omitted adjusting for BMI.**

130 **Results**

131 Higher BCAA intake was associated with younger age, measures of socioeconomic status
132 (white race, higher education and higher income per year), less likely to report current smoking, greater
133 physical activity, and lower history of CHD (**Table 1**). Yet, higher BCAA intake was also associated
134 with higher BMI and alcohol use, and higher glycemic load.

135 Geometric mean uncalibrated BCAA intake in our study was 10.9 g/d comprised of leucine (4.9
136 g/ d), isoleucine (2.8 g/ d) and valine (3.2 g/ d) (**Supplemental Table 1**). Major reported meat sources
137 of BCAAs were red meat (1.2g/day) and poultry (0.78 g/day) in our study population (Supplemental
138 Table 1). **Supplemental table 2** shows the quintile and median values for uncalibrated and calibrated
139 BCAA variables, and the quintile and median values of major reported food sources for meat intake are
140 presented in **supplemental table 3**.

141 A 20% increment in total BCAA intake (g/day and %energy) was associated with a 7% higher
142 risk for T2D (HR: 1.07; 95% CI: 1.05, 1.09) (**Table 2**). Similarly, a 20% increment in intake (g/d and
143 % of energy) for each of the BCAAs, including leucine, isoleucine and valine was associated with 7%
144 higher risk of T2D with similar HR: 1.07 (95% CI: 1.05, 1.09). Inferences were similar when
145 characterizing total BCAA intake as percent of protein intake, although isoleucine was more strongly
146 associated with T2D risk than leucine or valine (**Table 2**). For uncalibrated protein, model estimates
147 were similar with and without adjustment for BMI (**Table 2 and Supplemental table 4**), while with
148 calibrated protein the strength of the association was slightly higher with adjustment for BMI
149 (**supplemental table 5 and supplemental table 6**). Biomarker-calibration of energy and protein did
150 not appreciably affect the results (**Supplemental table 5**).

151 Likewise, in categorical analyses (**Table 2**), women reporting intake in the highest quintile of
152 uncalibrated BCAA (grams/day) had a 35% greater risk of T2D (HR 1.35, 95% CI 1.21, 1.50)
153 compared to those in the lowest quintile of intake. When the highest quintiles of uncalibrated protein
154 expressed as %energy/day (HR 1.21 95% CI 1.13, 1.29) or as a percentage of total protein intake (HR
155 1.08, 95% CI 1.01, 1.14) were compared to the lowest quintiles, the strength of the association was
156 attenuated, but remained significant (**Table 2**).

157 For total meat intake, a 20% increment increase was associated with a 4% higher risk of T2D
158 (HR: 1.04; 95% CI: 1.03, 1.05) (**Table 3**). Risk varied little across animal protein sources, although it
159 was lower in relation to fish and poultry intake compared to red meat. A 20% increment increase in
160 intake of red meat, fish, poultry and processed meat was associated with 3%, 2%, 1%, and 3% higher
161 risk of T2D, respectively (**Table 3**). In models jointly adjusted for BCAA and total meat intake, the
162 associations between BCAA intake (**grams**) and T2D were attenuated but retained significance (**Table**
163 **2, and supplemental table 7**).

164 **Discussion**

165 This study demonstrated that higher BCAA intake, with and without biomarker calibration of
166 protein exposure estimates, was associated with higher risk of T2D in the WHI OS and CT population.
167 Our results suggest that increased intake of dietary BCAAs may contribute to the risk of future T2D in
168 postmenopausal women. In addition to the prospective association with risk of T2D, our findings
169 showed that total meat intake was associated with increased risk of T2D in postmenopausal women.
170 The association of meat intake with T2D risk was attenuated in models jointly adjusted for BCAA
171 intake, but remained significant. These relations did not materially change with or without adjustment
172 for BMI.

173 Absolute intakes of total BCAAs in WHI women were similar to those of previous US cohorts
174 (medians across quintiles 1 through 5 were 10·1 -15·1 g/d in the Nurses' Health Study I, 12·0-18·0
175 g/day in the Nurses' Health Study II, and 12·6-18·8 for in the Health Professionals Follow-up Study
176 ~12·6) ⁽²⁰⁾. To provide perspective on how these ranges relate to dietary intake, four ounces of ground
177 beef contain 4·0 g BCAA and four chicken tenders contain 1·8g BCAA.

178 Studies that have examined the association of dietary BCAA consumption with T2D are scarce.
179 Our results corroborate those of the recent study by Zheng et al. ⁽²⁰⁾ which included three large,
180 prospective cohorts of US men and women, and reported that long-term consumption of BCAAs,
181 individually or in sum, was associated with increased risk of incident T2D. These associations were
182 independent of traditional diabetes risk factors, including BMI.

183 However, in a Japanese cohort (n=13,525), BCAA as a proportion of total protein (17·23% and
184 17·32% in men and women, respectively) were inversely associated with T2D in women (HR 0·57,
185 95% CI 0·36 to 0·90 comparing 3rd to 1st tertile), but were not significantly associated with T2D in
186 men ⁽¹¹⁾. This could be because of the population age (35 years and older) compared to WHI (50-79
187 years), the top two sources of BCAA in this population were cereals/potatoes and starches and
188 fish/shellfish, and the sensitivity and specificity of the T2D ascertainment by self-report compared to
189 HbA1c was 57·4% and 96·5%, respectively ^(2, 11).

190 Some studies of plasma BCAA levels have found associations with insulin resistance, which
191 may explain the adverse associations of BCAA intake with development of T2D ^(21, 22). It has been
192 shown that circulating branched-chain and aromatic amino acid levels predict insulin resistance index

193 over 6 years in normoglycemic young adult individuals even when accounting for baseline insulin
194 resistance ⁽²¹⁾. In the Framingham Offspring Study, higher plasma BCAA levels were correlated
195 positively with fasting insulin levels and predicted the future risk of T2D, a finding which was more
196 pronounced in obese individuals ⁽²²⁾. The positive association of plasma BCAA and insulin resistance
197 has also been found in studies across different settings ^(13, 23). A review by Newgard et al. ⁽²³⁾ concluded
198 that BCAA and related metabolites are positively associated with insulin resistance and T2D. In a
199 metabolomics study, plasma samples from obese and insulin-resistant versus lean and insulin sensitive
200 subjects were analyzed ⁽¹⁴⁾, showing from principal components analysis that most of the variance in
201 the data were explained by BCAA, which had the strongest association with insulin sensitivity, even
202 more than the lipid profiles.

203 Several mechanisms may explain the relationship between BCAA and T2D. Amino acids are
204 thought to play a significant role in the pathogenesis of insulin resistance, acting as gluconeogenic
205 precursors and stimulating hexosamine biosynthesis ⁽²²⁾. Moreover, amino acid signaling is integrated
206 by the mammalian target of rapamycin, a nutrient sensor that operates a negative feedback loop toward
207 insulin receptor substrate 1 signaling, promoting insulin resistance for glucose metabolism ⁽²⁴⁾. Glucose
208 utilization may also be impaired due to the inhibitory effect of amino acids on glucose transport and
209 phosphorylation ⁽²⁴⁾. Furthermore, amino acids affect glucose metabolism via stimulation of insulin and
210 glucagon secretion and by serving as substrates for gluconeogenesis ⁽⁵⁾. Infusion of amino acids to raise
211 plasma amino acid concentrations induced insulin resistance in skeletal muscle and stimulated
212 endogenous glucose production in healthy men ⁽²⁵⁾.

213 We also observed that higher meat intake increased the risk of T2D by 4% in postmenopausal
214 women, which is supported by a meta-analysis by Feskens and colleagues ⁽⁴⁾. The increased risk of
215 T2D associated with higher meat consumption might be explained in part by meat's contribution to
216 BCAA and/or possibly increasing the heme iron load. The BCAAs and tyrosine and phenylalanine are
217 mainly present in meat and dairy products, although available in many protein-rich foods ⁽²⁶⁾. For this
218 analysis, we focused on meat, rather than dairy, sources of BCAA's, as we were interested in whether
219 factors other than BCAA's explained the observed positive association between BCAA with diabetes
220 risk, and dairy has a weakly protective association with T2D. The earlier experimental elevations of
221 plasma amino acids by infusion, resulted in impaired insulin-stimulated glucose disposal and insulin-
222 mediated suppression of (hepatic) glucose production ⁽²⁷⁾. However, per 100 g of total meat, relative

223 risk of T2D increased 15% for (unprocessed) red meat, 13% for poultry, and 4% for processed meat.
224 Furthermore, higher meat intakes may contribute to increased heme iron load, and iron overload is
225 associated with increased T2D risk ⁽²⁶⁾.

226 The current study has important strengths including its prospective design, large sample size,
227 and long follow-up. Although T2D status, both treated and incident, was assessed by self-report
228 without adjudication or confirmation by clinical measures, the WHI self-report data for T2D have been
229 found to be highly consistent with medication use inventories provided by participants ⁽²⁸⁾owe. It is not
230 known whether circulating BCAAs are causes/mediators of insulin resistance or by-products of the
231 associated metabolic dysfunction. Thus, the present study explored the relation of dietary intake of
232 BCAAs with T2D, but cannot inform on causality.

233 Some limitations of the study need to be addressed. Diabetes was assessed using self-report,
234 which could result in misclassification error. However, a validation study in the WHI demonstrated
235 high concordance between self-reported treated diabetes and medication inventories ⁽²⁸⁾. Although we
236 controlled for several covariates, measurement error in these constructs may result in residual
237 confounding; women with higher BCAA intake had higher meat and alcohol intake, were more
238 educated, had higher income, and higher glycemic load. The role of other BCAA sources, such as
239 dairy, will be considered in work examining the role of dietary protein sources on diabetes risk within
240 WHI. **The response to dietary protein content may be dependent on an individual's degree of**
241 **underlying insulin resistance, determined by adiposity and BMI, but in our investigation adjusting for**
242 **BMI did not materially changed the associations.** Calibration using urinary nitrogen as a biomarker of
243 total protein intake was incorporated into the analysis and did not materially change effect estimates in
244 this analysis, but we did not have corresponding biomarkers of branched chain amino acid intake or
245 meat intake. The nutrient database relied on estimation for 26-50% of dietary amino acids, e.g., similar
246 foods or imputation. The BCAAs from meat were not able to be separated from total BCAAs.
247 Because of the observational design, conclusions regarding causality cannot be drawn. Also, this study
248 included postmenopausal women aged 50–79 years old from 40 designated clinical sites across, but not
249 representative of, the U.S. and therefore caution should be taken while generalizing these results to
250 other populations. Our findings indicated that higher BCAA and meat intakes were associated with
251 higher risk of T2D. Thus, it may be important to further consider dietary protein sources in dietary
252 recommendations to prevent T2D.

253 **Conclusion**

254 In a secondary analysis among a large cohort of postmenopausal women BCAA and meat
255 intake were associated with higher risk for T2D. The elevation in risk was very modest, but helps to
256 inform on future guidance for postmenopausal women at elevated risk for T2D.

257 **Acknowledgments**

258 *Financial Support*

259 The WHI program is funded by the National Heart, Lung, and Blood Institute, National Institutes of
260 Health, U.S. Department of Health and Human Services through contracts N01WH22110, 24152,
261 32100-2, 32105-6, 32108-9, 32111-13, 32115, 32118-32119, 32122, 42107-26, 42129-32, and 44221
262 and is registered with Clinicaltrials.gov (Record #NCT00000611). This manuscript was prepared in
263 collaboration with investigators of the WHI, and has been reviewed and/or approved by the Women's
264 Health Initiative (WHI). The short list of WHI investigators can be found at
265 <https://cleo.whi.org/researchers/SitePages/Write%20a%20Paper.aspx>. Dr. Beasley was supported by
266 career development award R00AG035002 sponsored by the National Institute of Aging. Dr. Phillips is
267 supported in part by FDA award RO1FD003527, VA awards HSR&D IIR 07-138 and I01-CX001025,
268 NIH awards [R21DK099716](#), DK066204, U01 DK091958, U01 DK098246, and a Cystic Fibrosis
269 Foundation award PHILLI12A0. The sponsors had no role in the design and conduct of the study;
270 collection, management, analysis, and interpretation of the data; and preparation, review, or approval of
271 the manuscript.

272 *Conflict of Interest*

273 Dr. Phillips declares that there is no duality of interest associated with this manuscript. With regard to
274 potential conflicts of interest, within the past several years, Dr. Phillips has served on Scientific
275 Advisory Boards for Boehringer Ingelheim, Janssen, and the Profil Institute for Clinical Research, and
276 has or had research support from Merck, Amylin, Eli Lilly, Novo Nordisk, Sanofi, PhaseBio, Roche,
277 Abbvie, Vascular Pharmaceuticals, Janssen, Glaxo SmithKline, and the Cystic Fibrosis Foundation. In
278 the past, he was a speaker for Novartis and Merck, but not for the last five years. Dr. Phillips is also
279 supported in part by the Veterans Health Administration (VA). This work is not intended to reflect the
280 official opinion of the VA or the U.S. government; TBD for others. Masoud Isanejad, Andrea LaCroix,

281 Cynthia Thomson, Lesley Tinker, Joseph C Larson, Qibin Qi, Lihong Qi, Rhonda M Cooper-DeHoff,
282 Ross L Prentice, and Jeannette M. Beasley had no potential conflict of interest to declare

283 *Authorship*

284 The authors' responsibilities were as follows—LFT, GES, BVH, YH, and RLP: designed the research;
285 LFT, GES, BVH, MLN, YMR, KM, CE, LP, and RLP: conducted the research; JCL: analyzed the data;
286 MI, JMB, AL, CT, LT,JL, QQ,LQ, RMC, LP, and RLP: wrote the manuscript; and MI and JMB: had
287 primary responsibility for the final content.

288

References

- 289 1. Adeva MM, Calviño J, Souto G *et al.* (2012) Insulin resistance and the metabolism of branched-
290 chain amino acids in humans. *Amino Acids* **43**(1), 171-181.
- 291 2. van Nielen M, Feskens EJ, Mensink M *et al.* (2014) Dietary protein intake and incidence of type 2
292 diabetes in Europe: the EPIC-InterAct Case-Cohort Study. *Diabetes Care* **37**(7), 1854-1862.
- 293 3. Ericson U, Sonestedt E, Gullberg B *et al.* (2013) High intakes of protein and processed meat
294 associate with increased incidence of type 2 diabetes. *Br J Nutr* **109**(06), 1143-1153.
- 295 4. Feskens EJ, Sluik D, van Woudenberg GJ (2013) Meat consumption, diabetes, and its
296 complications. *Current diabetes reports* **13**(2), 298-306.
- 297 5. Sluijs I, Beulens JW, van der, A D L *et al.* (2010) Dietary intake of total, animal, and vegetable
298 protein and risk of type 2 diabetes in the European Prospective Investigation into Cancer and Nutrition
299 (EPIC)-NL study. *Diabetes Care* **33**(1), 43-48.
- 300 6. Tinker LF, Sarto GE, Howard BV *et al.* (2011) Biomarker-calibrated dietary energy and protein
301 intake associations with diabetes risk among postmenopausal women from the Women's Health
302 Initiative. *Am J Clin Nutr* **94**(6), 1600-1606.
- 303 7. Wang ET, de Koning L, Kanaya AM (2010) Higher protein intake is associated with diabetes risk in
304 South Asian Indians: the Metabolic Syndrome and Atherosclerosis in South Asians Living in America
305 (MASALA) study. *J Am Coll Nutr* **29**(2), 130-135.
- 306 8. Malik VS, Li Y, Tobias DK *et al.* (2016) Dietary Protein Intake and Risk of Type 2 Diabetes in US
307 Men and Women. *Am J Epidemiol* .

- 308 9. Pan A, Sun Q, Bernstein AM *et al.* (2011) Red meat consumption and risk of type 2 diabetes: 3
309 cohorts of US adults and an updated meta-analysis. *Am J Clin Nutr* **94**(4), 1088-1096.
- 310 10. Katsanos CS, Kobayashi H, Sheffield-Moore M *et al.* (2006) A high proportion of leucine is
311 required for optimal stimulation of the rate of muscle protein synthesis by essential amino acids in the
312 elderly. *Am J Physiol Endocrinol Metab* **291**(2), 381.
- 313 11. Nagata C, Nakamura K, Wada K *et al.* (2013) Branched-chain amino acid intake and the risk of
314 diabetes in a Japanese community: the Takayama study. *Am J Epidemiol* **178**(8), 1226-1232.
- 315 12. Batch BC, Shah SH, Newgard CB *et al.* (2013) Branched chain amino acids are novel biomarkers
316 for discrimination of metabolic wellness. *Metab Clin Exp* **62**(7), 961-969.
- 317 13. Huffman KM, Shah SH, Stevens RD *et al.* (2009) Relationships between circulating metabolic
318 intermediates and insulin action in overweight to obese, inactive men and women. *Diabetes Care*
319 **32**(9), 1678-1683.
- 320 14. Newgard CB, An J, Bain JR *et al.* (2009) A branched-chain amino acid-related metabolic signature
321 that differentiates obese and lean humans and contributes to insulin resistance. *Cell metabolism* **9**(4),
322 311-326.
- 323 15. Langer RD, White E, Lewis CE *et al.* (2003) The Women's Health Initiative Observational Study:
324 baseline characteristics of participants and reliability of baseline measures. *Ann Epidemiol* **13**(9), S121.
- 325 16. Ritenbaugh C, Patterson RE, Chlebowski RT *et al.* (2003) The Women's Health Initiative Dietary
326 Modification trial: overview and baseline characteristics of participants. *Ann Epidemiol* **13**(9), S97.

- 327 17. Study, The Women's Health Initiative (1998) Design of the Women's Health Initiative clinical trial
328 and observational study. *Control Clin Trials* **19**(1), 61-109.
- 329 18. Patterson RE, Kristal AR, Tinker LF *et al.* (1999) Measurement characteristics of the Women's
330 Health Initiative food frequency questionnaire. *Ann Epidemiol* **9**(3), 178-187.
- 331 19. Anonymous US Department of Agriculture, Agricultural Research Service 2013. USDA National
332 Nutrient Database for Standard Reference, Release 26. <https://ndb.nal.usda.gov/ndb/search/list>.
- 333 20. Zheng Y, Li Y, Qi Q *et al.* (2016) Cumulative consumption of branched-chain amino acids and
334 incidence of type 2 diabetes. *Int J Epidemiol* , dyw143.
- 335 21. Wurtz P, Soininen P, Kangas AJ *et al.* (2013) Branched-chain and aromatic amino acids are
336 predictors of insulin resistance in young adults. *Diabetes Care* **36**(3), 648-655.
- 337 22. Wang TJ, Larson MG, Vasan RS *et al.* (2011) Metabolite profiles and the risk of developing
338 diabetes. *Nat Med* **17**(4), 448-453.
- 339 23. Newgard CB (2012) Interplay between lipids and branched-chain amino acids in development of
340 insulin resistance. *Cell metabolism* **15**(5), 606-614.
- 341 24. Tremblay F, Lavigne C, Jacques H *et al.* (2007) Role of dietary proteins and amino acids in the
342 pathogenesis of insulin resistance. *Annu.Rev.Nutr.* **27**, 293-310.
- 343 25. Krebs M, Krssak M, Bernroider E *et al.* (2002) Mechanism of amino acid-induced skeletal muscle
344 insulin resistance in humans. *Diabetes* **51**(3), 599-605.

- 345 26. Aregbesola A, Virtanen JK, Voutilainen S *et al.* (2015) Serum ferritin and glucose homeostasis:
346 change in the association by glycaemic state. *Diabetes Metab Res* **31**(5), 507-514.
- 347 27. Jiang R, Ma J, Ascherio A *et al.* (2004) Dietary iron intake and blood donations in relation to risk
348 of type 2 diabetes in men: a prospective cohort study. *Am J Clin Nutr* **79**(1), 70-75.
- 349 28. Margolis KL, Lihong Q, Brzyski R *et al.* (2008) Validity of diabetes self-reports in the Women's
350 Health Initiative: comparison with medication inventories and fasting glucose measurements. *Clin*
351 *Trials* **5**(3), 240-247.
- 352

Table 1 Characteristics at time of protein measurement¹ by quintile of uncalibrated total branched-chain amino acid intake (g/day) *

Characteristic	n=18·971		n=18·629		n=19·055		n=18·446		n=19·164		P-trend †
	Q1: < 7·7		Q2: 7·7 – <10·0		Q3: 10·0 - <12·3		Q4: 12·3 - <15·3		Q5: ≥ 15·3		
	Means	SD	Means	SD	Means	SD	Means	SD	Means	SD	
Age· mean	64·3	7·3	64·1	7·2	63·9	7·1	63·8	7·1	63·4	7·1	<0·001
Ethnicity §											
White ‡	14719	77·6	15853	85·1	16832	88·3	16574	89·9	16907	88·2	0·001
Black	2165	11·4	1264	6·8	1025	5·4	520	4·4	995	5·2	
Hispanic	860	4·5	634	3·4	501	2·6	468	2·5	623	3·3	
Other / Unknown	1227	6·5	878	4·7	697	3·7	584	3·2	639	3·3	
Education §											<0·001
≤ High school / GED	4865	25·6	4086	21·9	3667	19·2	3512	19·0	3468	18·1	
School after high school	7408	39·0	7061	37·9	7036	36·9	6650	36·1	7070	36·9	
College degree or higher	6698	35·3	7482	40·2	8352	43·8	8284	44·9	8626	45·0	
Income §											<0·001
≤ \$20·000	3601	19·0	2735	14·7	2497	13·1	2388	12·9	2777	14·5	
\$20·000 - \$49·999	8592	45·3	8311	44·6	8412	44·1	8255	44·8	8697	45·4	
≥ \$50·000	6778	35·7	7583	40·7	8146	42·7	7803	42·3	7690	40·1	
Body Mass Index· kg/m ² §											<0·001
Underweight (<18·5)	107	0·6	86	0·5	78	0·4	57	0·3	57	0·3	
Normal (18·5 - 24·9)	8293	43·7	7616	40·9	7400	38·8	6641	36·0	5600	29·2	
Overweight (25·0 – 29·9)	6422	33·9	6640	35·6	6843	35·9	6541	35·5	6582	34·3	
Obese (≥ 30·0)	4149	21·9	4287	23·0	7434	24·8	5207	28·2	692	36·1	

Current smoker §	1523	8.0	1266	6.8	1205	6.3	1124	6.1	1194	6.2	<0.001
Current alcohol use §	12550	66.2	13362	71.7	14104	74.0	13640	73.9	13753	71.8	<0.001
Hormone therapy use §											<0.001
Never	8114	42.8	7627	240.9	7771	40.8	7719	41.8	7985	41.7	
Past	2985	15.7	2935	15.8	2908	15.3	2780	15.1	2957	15.4	
Current	7872	41.5	8067	43.3	8376	44.0	7947	43.1	8222	42.9	
History of CHD §	582	3.1	523	2.8	501	2.6	427	2.3	442	2.3	<0.001
History of hypertension §	8346	44.0	7875	42.3	7995	42.0	7782	42.2	8404	43.9	0.770
Physical activity (METs/wk)	12.5	14.0	13.3	14.8	13.4	13.8	136.6	14.0	13.6	14.2	<0.001
Total energy intake (kcal)	976.1	238.1	1276.1	252.4	1515.0	282.3	1780.5	322.5	2352.4	574.0	<0.001
Glycemic Index	52.8	3.9	52.4	3.7	52.2	3.6	51.9	3.6	51.5	3.8	<0.001
Glycemic load	65.8	23.0	81.0	25.0	93.9	26.9	107.8	30.4	136.1	42.2	<0.001
Total meat (servings)	1.7	0.9	2.5	1.1	3.0	1.3	3.7	1.6	5.0	2.3	<0.001
Red meat (servings)	0.7	0.5	1.0	0.7	1.2	0.9	1.5	1.0	2.1	1.5	<0.001
Fish (servings)	0.3	0.3	0.5	0.4	0.5	0.4	0.6	0.5	0.8	0.6	<0.001
Poultry (servings)	0.4	0.4	0.6	0.5	0.8	0.6	0.9	0.6	1.2	0.8	<0.001
Processed meat (servings)	0.2	0.2	0.3	0.3	0.3	0.3	0.4	0.4	0.6	0.5	<0.001

* Baseline (or year 1 for DM trial participants)

† trend p-value from a linear (continuous and ordinal characteristics) or logistic (dichotomous characteristics) regression model with the characteristic of interest as a function of linear trend over the medians of each BCAA quintile.

‡ p-value trend is based on trend of BCAA quintiles on white ethnicity (yes/no)

§ frequency ± % (all such values)

5 Geometric means and standard deviations are presented, with trend tested over log transformed data

Table 2 Hazard ratios for the risk of diabetes by quintile of uncalibrated branched-chain amino acid (BCAA) intake

	Intake (grams)				Percent caloric intake				Percent protein intake			
	Events	Ann%	HR (95% CI) *	p-value †	Events	Ann%	HR (95% CI)	P	Events	Ann%	HR (95% CI)	P-value
Total BCAA				<0.001				<0.001				0.02
Q1	2043	0.88	1.00 (ref)		2083	0.91	1.00 (ref)		2100	0.88	1.00 (ref)	
Q2 vs. Q1	2023	0.86	1.04 (0.97, 1.12)		2186	0.88	1.00 (0.94, 1.06)		2246	0.99	1.05 (0.98, 1.11)	
Q3 vs. Q1	2186	0.90	1.10 (1.02, 1.19)		2209	0.92	1.05 (0.99, 1.12)		2388	0.98	1.05 (0.99, 1.11)	
Q4 vs. Q1	2242	0.95	1.17 (1.07, 1.27)		2315	0.98	1.11 (1.04, 1.18)		2292	0.98	1.07 (1.01, 1.14)	
Q5 vs. Q1	2748	1.15	1.35 (1.21, 1.50)		2449	1.06	1.21 (1.13, 1.29)		2216	0.92	1.08 (1.01, 1.14)	
Continuous ‡			1.07 (1.05, 1.09)	<0.001			1.07 (1.05, 1.09)	<0.001			1.11 (1.01, 1.22)	0.03
Leucine				<0.001				<0.001				0.01
Q1	2016	0.88	1.00 (ref)		2124	0.90	1.00 (ref)		2086	0.88	1.00 (ref)	
Q2 vs. Q1	2097	0.87	1.05 (0.98, 1.12)		1998	0.88	1.01 (0.95, 1.07)		2379	1.00	1.06 (1.00, 1.13)	
Q3 vs. Q1	2158	0.89	1.09 (1.00, 1.17)		2167	0.92	1.06 (1.00, 1.13)		2328	0.98	1.05 (0.99, 1.12)	
Q4 vs. Q1	2317	0.96	1.16 (1.06, 1.27)		2505	0.98	1.11 (1.05, 1.18)		2251	0.95	1.06 (1.00, 1.13)	
Q5 vs. Q1	2654	1.15	1.33 (1.19, 1.48)		2448	1.06	1.23 (1.15, 1.31)		2198	0.94	1.09 (1.02, 1.16)	
Continuous ‡			1.07 (1.05, 1.09)	<0.001			1.07 (1.05, 1.09)	<0.001			1.10 (1.01, 1.20)	0.03
Isoleucine				<0.001				<0.001				<0.001
Q1	2020	0.87	1.00 (ref)		2066	0.89	1.00 (ref)		1908	0.81	1.00 (ref)	
Q2 vs. Q1	2025	0.87	1.06 (0.99, 1.14)		2175	0.88	1.02 (0.96, 1.08)		2184	0.92	1.04 (0.98, 1.11)	
Q3 vs. Q1	2183	0.90	1.12 (1.03, 1.21)		2169	0.92	1.06 (1.00, 1.13)		2293	0.97	1.06 (1.00, 1.13)	
Q4 vs. Q1	2248	0.95	1.18 (1.08, 1.29)		2286	0.98	1.12 (1.06, 1.20)		2354	0.99	1.09 (1.02, 1.16)	

Q5 vs. Q1	2766	1.16	1.38 (1.24, 1.54)		2546	1.09	1.23 (1.16, 1.31)		2503	1.06	1.18 (1.11, 1.26)	
Continuous ‡			1.07 (1.05, 1.09)	<0.001			1.07 (1.05, 1.09)	<0.001			1.27 (1.15, 1.40)	<0.001
Valine				<0.001				<0.001				0.80
Q1	2062	0.90	1.00 (ref)		2052	0.91	1.00 (ref)		2188	0.95	1.00 (ref)	
Q2 vs. Q1	2034	0.86	1.02 (0.95, 1.10)		2284	0.91	1.04 (0.98, 1.11)		2362	1.00	1.00 (0.95, 1.07)	
Q3 vs. Q1	2232	0.91	1.09 (1.01, 1.18)		2025	0.92	1.05 (0.99, 1.12)		2328	0.99	1.02 (0.96, 1.08)	
Q4 vs. Q1	2226	0.94	1.12 (1.03, 1.23)		2381	0.97	1.11 (1.05, 1.19)		2311	0.97	1.05 (0.98, 1.11)	
Q5 vs. Q1	2688	1.14	1.30 (1.17, 1.45)		2500	1.05	1.23 (1.15, 1.31)		2053	0.85	0.98 (0.92, 1.05)	
Continuous ‡			1.07 (1.05, 1.09)	<0.001			1.07 (1.05, 1.09)	<0.001			0.98 (0.90, 1.07)	0.62

* Hazard ratios and confidence intervals from proportional hazards models with incident diabetes as a function of the protein variable of interest adjusted for age, ethnicity, BMI, education, income, history of CHD, current smoking, current alcohol use, physical activity, hypertension, family history of diabetes, hormone use, glycemic load, glycemic index, and total energy intake. Models are additionally stratified within the model for WHI intervention arms and 5-year age groups

†p-values for categorical protein variables are from a separate model looking at linear trend over the medians of each quintile.

‡ Hazard ratios, confidence intervals, and p-values in the continuous models for a 20% increase of the protein value of interest

Table 3 Hazard ratios for the risk of diabetes by quintile of meat intake by MPED categories (adjusted for BMI).

	Events	Ann%	HR (95% CI) *	P-value †
Total Meat				<0.001
Q1	1707	0.72	1.00 (ref)	
Q2 vs. Q1	2045	0.87	1.12 (1.05, 1.19)	
Q3 vs. Q1	2222	0.91	1.15 (1.07, 1.22)	
Q4 vs. Q1	2321	0.99	1.16 (1.08, 1.24)	
Q5 vs. Q1	2947	1.27	1.28 (1.19, 1.38)	
Continuous ‡			1.04 (1.03, 1.05)	<0.001
Red meat				<0.001
Q1	1744	0.74	1.00 (ref)	
Q2 vs. Q1	2095	0.87	1.08 (1.01, 1.15)	
Q3 vs. Q1	2178	0.92	1.10 (1.03, 1.17)	
Q4 vs. Q1	2391	1.01	1.16 (1.08, 1.24)	
Q5 vs. Q1	2834	1.21	1.19 (1.11, 1.28)	
Continuous ‡			1.03 (1.02, 1.04)	<0.001
Fish				0.002
Q1	2181	0.97	1.00 (ref)	
Q2 vs. Q1	2184	0.92	0.97 (0.92, 1.03)	
Q3 vs. Q1	2199	0.93	1.00 (0.95, 1.07)	
Q4 vs. Q1	2306	0.92	0.99 (0.93, 1.05)	
Q5 vs. Q1	2372	1.01	1.07 (1.01, 1.14)	
Continuous ‡			1.02 (1.01, 1.03)	0.001
Poultry				0.010
Q1	1918	0.82	1.00 (ref)	
Q2 vs. Q1	2200	0.92	1.03 (0.97, 1.10)	
Q3 vs. Q1	2227	0.96	1.04 (0.98, 1.11)	
Q4 vs. Q1	2217	0.99	1.06 (1.00, 1.13)	
Q5 vs. Q1	2680	1.06	1.06 (1.00, 1.13)	
Continuous ‡			1.01 (1.00, 1.02)	0.010
Processed meat				<0.001
Q1	1624	0.72	1.00 (ref)	
Q2 vs. Q1	2224	0.85	1.08 (1.02, 1.16)	
Q3 vs. Q1	2278	0.96	1.13 (1.06, 1.21)	
Q4 vs. Q1	2436	1.07	1.15 (1.08, 1.23)	
Q5 vs. Q1	2680	1.16	1.17 (1.10, 1.25)	
Continuous ‡			1.03 (1.02, 1.04)	<0.001

* Hazard ratios and confidence intervals from proportional hazards models with incident diabetes as a function of the food group of interest adjusted for age, ethnicity, education, income, history of CHD, current smoking, current alcohol use, physical activity, hypertension, family history of diabetes, hormone use, glycemic load, glycemic index, total energy intake, and BMI. Models are additionally stratified within the model for WHI hormone therapy arms and 5-year age groups

† p-values for categorical food group variables are from a separate model looking at linear trend over the medians of each quintile.

‡ Hazard ratios, confidence intervals, and p-values in the continuous models for a 20% increase of the food group value of interest